Detail akcie Quoin Pharma Sp ADS online

Business Summary: Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Quoin Pharmaceuticals Ltd - ADR revenues was not reported. Net loss increased 72% to $11.5M. Higher net loss reflects Development of therapeutic products segment loss increase of 65% to $11.8M. Basic Earnings per Share excluding Extraordinary Items decreased from -$1.96 to -$19.50.